Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Shu

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
The Journal of Clinical Endocrinology and Metabolism|August 4, 2021
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult HypoparathyroidismAliya A Khan, Lars Rejnmark, Mishaela Rubin, et al.
Hormone Research in Paediatrics|March 6, 2025
Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final ResultsAristides K Maniatis, Paul S Thornton, Ulhas M Nadgir, et al.
The Journal of Clinical Endocrinology and Metabolism|October 9, 2021
Response to Letter to the Editor From L. Sävendahl et al: "Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial"Paul S Thornton, Aristides K Maniatis, Elena Aghajanova, et al.
The Journal of Clinical Endocrinology and Metabolism|December 20, 2025
Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial ResultsBeverly M K Biller, Aleksandra Gilis-Januszewska, Mirjana Doknic, et al.
The Journal of Clinical Endocrinology and Metabolism|October 8, 2024
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway TrialBart L Clarke, Aliya A Khan, Mishaela R Rubin, et al.
JAMA Pediatrics|November 17, 2025
Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical TrialRavi Savarirayan, Ciara McDonnell, Carlos A Bacino, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 22, 2022
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway TrialAliya A Khan, Mishaela R Rubin, Peter Schwarz, et al.
Advances in Therapy|May 1, 2024
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway TrialLars Rejnmark, Elvira O Gosmanova, Aliya A Khan, et al.
The Journal of Clinical Endocrinology and Metabolism|April 16, 2022
Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year ResultsAristides K Maniatis, Samuel J Casella, Ulhas M Nadgir, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 21, 2026
Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-TrialLars Rejnmark, Elvira O Gosmanova, Aliya A Khan, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
The Journal of Clinical Endocrinology and Metabolism|August 4, 2021
PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult HypoparathyroidismAliya A Khan, Lars Rejnmark, Mishaela Rubin, et al.
Hormone Research in Paediatrics|March 6, 2025
Children with Growth Hormone Deficiency Treated with Lonapegsomatropin Demonstrated Sustained Height Improvements for up to 6 Years: enliGHten Trial Final ResultsAristides K Maniatis, Paul S Thornton, Ulhas M Nadgir, et al.
The Journal of Clinical Endocrinology and Metabolism|October 9, 2021
Response to Letter to the Editor From L. Sävendahl et al: "Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial"Paul S Thornton, Aristides K Maniatis, Elena Aghajanova, et al.
The Journal of Clinical Endocrinology and Metabolism|December 20, 2025
Efficacy and Safety of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: foresiGHt Trial ResultsBeverly M K Biller, Aleksandra Gilis-Januszewska, Mirjana Doknic, et al.
The Journal of Clinical Endocrinology and Metabolism|October 8, 2024
Efficacy and Safety of TransCon PTH in Adults With Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway TrialBart L Clarke, Aliya A Khan, Mishaela R Rubin, et al.
JAMA Pediatrics|November 17, 2025
Once-Weekly Navepegritide in Children With Achondroplasia: The APPROACH Randomized Clinical TrialRavi Savarirayan, Ciara McDonnell, Carlos A Bacino, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 22, 2022
Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway TrialAliya A Khan, Mishaela R Rubin, Peter Schwarz, et al.
Advances in Therapy|May 1, 2024
Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway TrialLars Rejnmark, Elvira O Gosmanova, Aliya A Khan, et al.
The Journal of Clinical Endocrinology and Metabolism|April 16, 2022
Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year ResultsAristides K Maniatis, Samuel J Casella, Ulhas M Nadgir, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 21, 2026
Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-TrialLars Rejnmark, Elvira O Gosmanova, Aliya A Khan, et al.
Pageof 12